LYMPHOMAS

"Treatment with liso-cel resulted in high response rates and durable complete responses in a patient population considered to be high risk.”

John Kuruvilla, MD, FRCPC, discussed the positive findings for pembrolizumab compared with brentuximab vedotin in patients with Hodgkin lymphoma in the KEYNOTE-204 study.

Compelling objective responses and safety results were demonstrated with the combination of cirmtuzumab and ibrutinib in cohorts of patients with mantle cell lymphoma and chronic lymphocytic leukemia, who were treated in the phase 1b/2 clinical trial.

Chimeric antigen receptor T-cell therapy lead to poor overall survival outcomes it patients who were 75 years or older with relapsed/refractory diffuse large B-cell lymphoma compared with patients aged 70 to 74 years, but progression-free survival was comparable between the 2 groups.

In an interview with Targeted Oncology, Sarah C. Rutherford, MD, discussed the phase 1 findings for the combination of venetoclax plus standard chemoimmunotherapy as treatment of patients with aggressive B-cell lymphomas.

Interim analysis of the ZUMA-5 study indicates that patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor T-cell therapy of axicabtagene ciloleucel had high rates of response and demonstrated the agent's manageable safety profile.

Pembrolizumab should be considered the preferred treatment option and the new standard of care in relapsed/refractory classical Hodgkin's lymphoma in patients that have relapsed post autologous stem cell transplant or are ineligible for autologous stem cell transplant.

"Fast Track Designation for lymphoplasmacytic lymphoma and Waldenstrom’s macroglobulinemia further supports our clinical development strategy to quickly and efficiently provide these patients with an effective therapeutic alternative."

“This randomized phase III study for the first time provides prospective long-term results on survival and other end points of interest after standard treatment with CHOP in patients with PTCL beyond 60 years who represent the majority of [patients with] PTCL, generally less eligible for more intense therapies like autologous and allogeneic transplantation."

"Single-agent trametinib had low rates of clinical activity in patients with heavily pretreated, metastatic cancers harboring non-V600 mutations in BRAF. This contrasts with a number of case reports, largely in melanoma, showing responses in patients with these mutations."

Tatyana Feldman, MD, discusses the design and efficacy of the ECHELON-1 trial investigating brentuximab vedotin with chemotherapy in patients with stage III or IV Hodgkin lymphoma after a 3-year update.

Few options exist for patients with relapsed or refractory large B-cell lymphomas who have already undergone 2 rounds of systemic therapy. New research shows axicabtagene ciloleucel might be a strong option, but community oncologists must play a role in patient identification and post-treatment follow-up.

“This designation supports the advancement of Kymriah, which could potentially address an unmet need in certain patients with follicular lymphoma, as we strive to reimagine medicine at Novartis. These patients are often faced with the burden of several years of various treatments as their disease continues to progress.”

In an interview with Targeted Oncology, Sonali M. Smith, MD, discussed the treatment landscape for patients with indolent non-Hodgkin lymphoma. In particular, she highlighted the data supporting the use of rituximab plus lenalidomide in patients with follicular lymphoma and marginal zone lymphoma.

David Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.

Sonali M. Smith, MD, discusses&nbsp;how to handle patients with follicular lymphoma when they relapse, especially if they are early progressors.<br /> &nbsp;

The FDA has granted Fast Track Therapy designation to ME-401, an investigational selective oral inhibitor of phosphatidylinositol 3-kinase inhibitor as treatment of patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.

Brad Kahl, MD, discusses the treatment options for patients with indolent lymphomas who are relapsed/refractory.

Efficacy analyses by cell of origin and by MYC and BCL2 double expression status showed a trend toward improved outcomes of patients treated on the polatuzumab vedotin-containing arm regardless of cell of origin or MYC and BCL2 doubkle expression status.

Treatment with SGX301 led to statistically significant responses in patients with cutaneous T-cell lymphoma, according to preliminary top-line results from the pivotal phase III FLASH trial released by Soligenix.

Tatyana Feldman, MD, director of T cell program at the John Theurer Cancer Center, Hackensack Meridian Health, discusses how research is now building upon the positive results from the phase III ECHELON-1 study, which was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.<br /> &nbsp;

Jason Westin, MD, MS, FACP, discusses the current treatment options for patients with diffuse large B-cell lymphoma that are available besides rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.

The largest prospective dataset in previously untreated diffuse large B-cell lymphoma revealed the molecular heterogeneity of diffuse large B-cell lymphoma with potential treatment targets harbored by the cell-of-origin subtypes, based on data from a phase III GOYA study.&nbsp;<br /> &nbsp;

The FDA has placed a partial clinical hold on the phase I trial of ACTR707 in combination with rituximab in patients with relapsed/refractory B-cell lymphoma from Unum Therapeutics, following the submission of a safety report from the company. The FDA notified Unum of the hold verbally on March 4. Unum Therapeutics acknowledged the partial clinical hold in filings with the Securities and Exchange commission.

The addition of tazemetostat to rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone was generally well tolerated and demonstrated early anti-tumor activity in patients with newly diagnosed diffuse large B-cell lymphoma, according to the findings from the phase Ib study.